The University of North Carolina Bone Marrow Transplant and Cellular Therapy Program at UNC Health provides outstanding care for leukemia, lymphoma and myeloma patients undergoing either stem cell transplant or CAR T-cell therapies and is nationally recognized for its outstanding transplant patient survival outcomes as well as overall patient satisfaction.
Our program performs standard autologous stem cell transplants as well as allogeneic stem cell transplants using HLA-matched, HLA-mismatched and haplo-identical donors. We also administer all the current FDA-approved CAR T-cells for hematologic malignancies as well as FDA-approved TIL therapy for melanoma and FDA-approved gene therapy for sickle cell anemia and beta thalassemia.
In addition to the broad range of FDA-approved therapies, our program, in partnership with the UNC Lineberger Comprehensive Cancer Center, has an extremely robust research and clinical trials portfolio with multiple cellular therapy clinical trials treating patients with different conditions ranging from solid malignancies, such as breast and lung cancer, to autoimmune diseases, such as lupus and myasthenia gravis.
Most of the cellular immunotherapy products used in our studies are created at UNC Lineberger’s Advanced Cellular Therapeutics Facility, which utilizes Good Manufacturing/ Tissue Practices and is located within five miles of our clinics.